MAM
CRMD icon

Meeder Asset Management’s CorMedix CRMD Stock Holding History

Meeder Asset Management’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,144
Closed -$21K – 2529
2021
Q1 		$21K Buy
+2,144
New +$22.6K ﹤0.01% 1386
2020
Q1 		– Sell
-574
Closed -$4K – 2354
2019
Q4 		$4K Buy
+574
New +$3.51K ﹤0.01% 1834

Other funds holding CRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EIM
Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Meeder Asset Management's CRMD Position: Q2 2021 in Review

Meeder Asset Management sold out of CorMedix (CRMD) in Q2 2021, closing a stake of 2,144 shares — an estimated $21K sold.

Meeder Asset Management first reported a position in CRMD in Q4 2019 and held it in 2 quarters. The position peaked at $21K in Q1 2021. 79 funds tracked by Wall St. Rank hold CRMD as of Q2 2021.

  • Meeder Asset Management reported no remaining CorMedix position as of Q2 2021 after selling out during the quarter.
  • Meeder Asset Management sold 2,144 CorMedix shares in Q2 2021, an estimated $21K.
  • Meeder Asset Management first reported a position in CorMedix in Q4 2019 and held it in 2 quarters.
  • Meeder Asset Management's CorMedix position peaked at $21K in Q1 2021.
  • 79 funds tracked by Wall St. Rank held CorMedix as of Q2 2021.

Based on Meeder Asset Management's 13F filing for Q2 2021, filed 9 Aug 2021.